Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study

Journal of Diabetes Investigation ◽

10.1111/jdi.13181 ◽

2020 ◽

Vol 11 (3) ◽

pp. 662-671

Author(s):

Kohei Kaku ◽

Hiroyuki Isaka ◽

Taishi Sakatani ◽

Junko Toyoshima

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label Extension ◽

Phase Iii Study

Download Full-text

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13922 ◽

2019 ◽

Vol 22 (4) ◽

pp. 540-548 ◽

Author(s):

Eiichi Araki ◽

Hirotaka Watada ◽

Yasuko Uchigata ◽

Osamu Tomonaga ◽

Hitomi Fujii ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review3 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/decision1 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review2 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v1/review1 ◽

2019 ◽

Author(s):

Torben Biester

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/review1 ◽

2019 ◽

Author(s):

Torben Biester

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Author response for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/response1 ◽

2019 ◽

Author(s):

Eiichi Araki ◽

Hirotaka Watada ◽

Yasuko Uchigata ◽

Osamu Tomonaga ◽

Hitomi Fujii ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Author Response ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial"

10.1111/dom.13922/v2/decision1 ◽

2019 ◽

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Open Label Phase

Download Full-text

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT ‐2 study

Diabetes Obesity and Metabolism ◽

10.1111/dom.14362 ◽

2021 ◽

Author(s):

Eiichi Araki ◽

Chantal Mathieu ◽

Toshihiko Shiraiwa ◽

Hajime Maeda ◽

Hiroki Ikeda ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Therapy ◽

Subgroup Analysis ◽

Japanese Patients ◽

Efficacy And Safety

Download Full-text

Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13322 ◽

2018 ◽

Vol 20 (8) ◽

pp. 1944-1950 ◽

Author(s):

Thomas C. Blevins ◽

Abhijit Barve ◽

Bin Sun ◽

Michael Ankersen

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Study

Download Full-text